Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by FELDMEN, C.
Right arrow Articles by PARKE, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FELDMEN, C.
Right arrow Articles by PARKE, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1982 British Society for Rheumatology

research-article

TOXIC EPIDERMAL NECROLYSIS IN A PATIENT TREATED WITH GOLD SLTS AND BENOXAPROFEN

CHARLOTTE FELDMEN1,, I. LAMPERT2 and ANNE PARKE3

1Department of Rheumatology Ealing Hospital Southall, Middlesex UB1 3HW
2Histopathology, Ealing Hospital Southall, Middlesex UB1 3HW
3Rheumatology Unit, Hammersmith Hospital London W12 0HS

Correspondence to: Requests for reprints to Dr. C. Feldman.

Fatal toxic epdiermal necrolyis is described in a patient, trated concurrently with sodium aurothiomalate and benoxaprofen, who had previously had these two drugs separately, with only minor mucocutaneous problems while on gold, and no adverse effects from benoxaprofen.

It is suggested that benoxaprofen could act synergistically with gold, resulting in enhancement of mucocutaneous side-effects, which are common to both these drugs.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.